Immune response to nanomaterials: Implications for medicine and literature review

Current Allergy and Asthma Reports

Volumn 13, Issue 1, 2013, Pages 50-57

  Syed, Saad ^a   Zubair, Adeel ^a   Frieri, Marianne ^b  

^a Nassau University Medical Center ^*  (United States)

^b NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advances; Allergy; Immune response; Immunology; Nanomaterials; NF B pathway; Nuclear factor B; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ALUMINUM OXIDE; CARBON NANOTUBE; CHITOSAN; GAMMA INTERFERON; GOLD NANOPARTICLE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 6; NANOMATERIAL; QUANTUM DOT; REACTIVE OXYGEN METABOLITE; SAQUINAVIR; SILICON DIOXIDE; SILVER NANOPARTICLE; SMALL INTERFERING RNA; TITANIUM DIOXIDE;

ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; GENOTOXICITY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NANOANALYSIS; NANOPHARMACEUTICS; NANOTOXICOLOGY; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; REVIEW; SILICOSIS; TH1 TH2 BALANCE; TOXICITY TESTING; TRANSCRIPTION REGULATION;

EID: 84872609432     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-012-0302-3     Document Type: Review

References (104)

1. Saltan N, Kutlu HM, Hür D, Işcan A, Say R. Interaction of cancer cells with magnetic nanoparticles modified by methacrylamido-folic acid. Int J Nanomedicine. 2011;6:477-8.
2. Gao T, Li Q, Wang T. Sonochemical Synthesis, Optical Properties, and Electrical Properties of Core/Shell-Type ZnO Nanorod/CdS Nanoparticle Composites. Chem Mater. 2005;17:887-92. (Pubitemid 40261344)
3. Aitken RJ, Chaudhry MQ, Boxall ABA, Hull M. Manufacture and use of nanomaterials: current status in the UK and global trends. Occup Med Oxf Engl. 2006;56:300-6. (Pubitemid 44304820)
4. Yoshida M, Lahann J. Smart Nanomaterials. ACS Nano. 2008;2:1101-7.
5. Lonkar P, Dedon PC. Reactive species and DNA damage in chronic inflammation: reconciling chemical mechanisms and biological fates. Int J Cancer. 2011;128:1999-2009.
6. Mikhaylov G, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol. 2011;6:594-602.
7. • Fan K, et al. Magnetoferritin nanoparticles for targeting and visualizing tumour tissues. Nat Nanotechnol. 2012. This paper examined over 400 clinical specimens from patients with nine types of cancer and verified that nanoparticles can distinguish cancerous cells from normal cells with a sensitivity of 98 % and specificity of 95 %.
8. Nelson AM, et al. Tissue Regeneration, Stem Cells, and Wound Healing. J Invest Dermatol. 2011;132:S135-48.
9. Klimek L, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy. 2011;41:1305-12.
10. • Teste B, et al. Microchip integrating magnetic nanoparticles for allergy diagnosis. Lab Chip. 2011;21:b4207-13. This paper reported on the development of a simple and easy to use microchip dedicated to allergy diagnosis which combines both the advantages of homogeneous immunoassays and heterogeneous immunoassays.
11. Liu Z, et al. Local nasal immunotherapy: efficacy of Dermatophagoides farinae-chitosan vaccine in murine asthma. Int Arch Allergy Immunol. 2009;150:221-8.
12. Mahajan SD, et al. Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA. Patholog Res Int. 2011.
13. Frieri M, et al. Vascular Endothelial Growth Factor and Tumor Necrosis Factor Alpha in Brain Tissue from HIV Positive Patients with/without Central Nervous System Lesions FOCIS. Clin Immunol. 2010.
14. Mahajan SD. Enhancing the delivery of anti retroviral drug «Saquinavir» across the blood brain barrier using nanoparticles. Curr HIV Res. 2010;8:396-404.
15. Powers KW, Palazuelos M, Moudgil BM, Roberts SM. Characterization of the size, shape, and state of dispersion of nanoparticles for toxicological studies. Nanotoxicology. 2007;1:42-51. (Pubitemid 46570246)
16. Buzea C, Pacheco I, Robbie K. Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases. 2007;2:MR17-71.
17. Hansen S. A global view of regulations affecting nanomaterials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2:441-9.
18. Cuenya BR. Synthesis and catalytic properties of metal nanoparticles: Size, shape, support, composition, and oxidation state effects. Thin Solid Films. 2010;518:3127-50.
19. Kim B, Rutka J, Chan W. Nanomedicine. N Engl J Med. 2010;363:2434-43.
20. Jiang W, Kim B, Rutka J, Chan W. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol. 2008;3:145-50. (Pubitemid 351355131)
21. Sanhai W, Sakamoto J, Canady R, Ferrari M. Seven challenges for nanomedicine. Nat Nanotechnol. 2008;3:242-4. (Pubitemid 351668048)
22. Kandasamy R, et al. Isatin down-regulates expression of atrial natriuretic peptide receptor A and inhibits airway inflammation in a mouse model of allergic asthma. Int Immunopharmacol. 2010;10:218-25.
23. Pan YH, et al. 3D morphology of the human hepatic ferritin mineral core: new evidence for a subunit structure revealed by single particle analysis of HAADF-STEM images. J Struct Biol. 2009;166:22-31.
24. Kalgaonkar S, Lonnerdal S. Receptor-mediated uptake of ferritin-bound iron by human intestinal Caco-2 cells. J Nutr Biochem. 2009;20:304-11.
25. Des Rieux A, et al. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur J Pharm Sci. 2005;25:455-65. (Pubitemid 40853873)
26. Frieri M. Food Hypersensitivity and Adverse Reactions: A Practical Guide for Diagnosis and Management. Chapter 2. New York: Marcel Dekker; 1999. p. 39-50.
27. Shahzad G, Mustacchia P, Frieri M. Role of mucosal inflammation in eosinophilic esophagitis: Review of the literature, International Scholarly Research Network (ISRN). Gastroenterology. 2011;2011:Article ID 468073.
28. Fievez V, et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm. 2009;73:16-24.
29. Verma A, et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater. 2008;7:588-95.
30. Balasubramaniana S, Jittiwatb J, Manikandanc J, Ongd C, Yua L. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials. 2010;31:2034-42.
31. Deng X, et al. Translocation and fate of multi-walled carbon nanotubes in vivo. Carbon. 2007;45:1419-24. (Pubitemid 46829028)
32. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm. 2008;5:316-27. (Pubitemid 351579134)
33. Yang RS, et al. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ Health Perspect. 2007;5:1339-43. (Pubitemid 47471259)
34. Garnett MC, Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup Med. 2006;56:307-11. (Pubitemid 44304821)
35. Chompoosor A, et al. The Role of Surface Functionality on Acute Cytotoxicity, ROS Generation and DNA Damage by Cationic Gold Nanoparticles. Small. 2010;20:2246-9.
36. Romoser A, et al. Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts. Toxicol Lett. 2012;210:293-301.
37. Carlson C, et al. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B. 2008;112:13608-19.
38. Kim S, et al. Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells. Toxicol In Vitro. 2009;23:1076-84.
39. Arora S, Jain J, Rajwade JM. Paknikar KM Cellular responses induced by silver nanoparticles: in vitro studies. Toxicol Lett. 2008;179:93-100.
40. Foldbjerg R, Dang D, Autrup H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch Toxicol. 2011;85:743-50.
41. •• Lee S, Yun HS, Kim SH. The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis. Biomaterials. 2011;32:9434-43. This paper stated that the mesoporous silica nanoparticles exhibit better biocompatibility than colloidal silica and promise excellent potential usage in the field of biomedical and biotechnological applications.
42. Napierska D, Thomassen L, Lison D, Martens J, Hoet P. The nanosilica hazard: another variable entity. Part Fibre Toxicol. 2010;7:39.
43. Mahler G, et al. Oral exposure to polystyrene nanoparticles affects iron absorption. Nat Nanotechnol. 2012;7:264-71.
44. Yamashita K, et al. Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nat Nanotechnol. 2011;6:321-8.
45. Downs T, et al. Silica nanoparticles administered at the maximum tolerated dose induce genotoxic effects through an inflammatory reaction while gold nanoparticles do not. Mutat Res. 2012;745:38-50.
46. Niidome T, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release. 2006;114:343-7. (Pubitemid 44310822)
47. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009;6:1-16.
48. Vonarbourg A, Passirani C. saulnier, S., Benoit, J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials. 2006;27:4356-73. (Pubitemid 43674179)
49. Kah JC, et al. Critical parameters in the pegylation of gold nanoshells for biomedical applications: an in vitro macrophage study. J Drug Target. 2009;17:181-93.
50. Lipka J, et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials. 2010;31:6574-81.
51. Shah NB, et al. Blood- Nanoparticles interactions and in vivo biodistribution: Impact of surface PEG ligand properties. Mol Pharm. 2012.
52. Yang ST. Covalently PEGylated carbon nanotubes with stealth character in vivo. Small. 2008;4:940-4.
53. Liu AH. In Vivo studies of the toxicity of multi-wall carbon nanotubes. Adv Mater Res. 2011;345:287-91.
54. Crouzier D, et al. Carbon nanotubes induce inflammation but decrease the production of reactive oxygen species in lung. Toxicology. 2010;272:39-45.
55. Frieri M. Advances in understanding allergic asthma. Allergy Asthma Proc. 2007;28:614-9.
56. Inouea K, Yanagisawaa R, Koikea E, Nishikawab M, Takano H. Repeated pulmonary exposure to single-walled carbon nanotubes exacerbates allergic inflammation of the airway: Possible role of oxidative stress. Free Radic Biol Med. 2010;48:924-34.
57. Thurnherr T, et al. A comparison of acute and long-term effects of industrial multiwalled carbon nanotubes on human lung and immune cells in vitro. Toxicol Lett. 2011;200:176-86.
58. Toyama T, et al. A case of toxic epidermal necrolysis-like dermatitis evolving from contact dermatitis of the hands associated with exposure to dendrimers. Contact Dermatitis. 2011;59:122-3.
59. Hamman J. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Mar Drugs. 2010;8:1305-22.
60. Canal C, Aparicio RM, Vilchez A, Esquena J, García-Celma MJ. Drug Delivery Properties of Macroporous Polystyrene Solid Foams. J Pharm Pharm Sci. 2012;15:197-207.
61. Luo Z, Zou C, Syed S, Syarbaini L, Chen G. Highly monodisperse chemically reactive sub-micrometer particles: polymer colloidal photonic crystals. Colloid Polym Sci. 2011;290:141-50.
62. Xia T, et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 2006;6:1794-807. (Pubitemid 44327550)
63. Poplawski T, et al. Cytotoxicity and genotoxicity of glycidyl methacrylate. Chem Biol Interact. 2009;180:69-78.
64. Manna SK, et al. Single-walled carbon nanotube induces oxidative stress and activates nuclear transcription. Nano Lett. 2005;5:1676-84. (Pubitemid 41396145)
65. Schipper M, et al. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat Nanotechnol. 2008;3:216-21. (Pubitemid 351506336)
66. Sayes C, Marchione A, Reed KL, Warheit DB. Comparative pulmonary toxicity assessments of C60 water suspensions in rats: Few differences in fullerene toxicity in vivo in contrast to in vitro profiles. Nano Lett. 2007;7:2399-406. (Pubitemid 47310138)
67. Circu M, Aw T. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2009;48:749-62.
68. Hamanaka R, Chandel N. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem Sci. 2010;35:505-13.
69. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1-13.
70. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Oxford University Press; 2007. p. 1-677.
71. Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev. 2007;219:88-102. (Pubitemid 47390004)
72. Winterbourn C. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol. 2008;4:278-86. (Pubitemid 351550893)
73. Forman HJ. Use and abuse of exogenous H2O2 in studies of signal transduction. Free Radic Biol Med. 2007;42:926-32. (Pubitemid 46356902)
74. Xia T, et al. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. ACS Nano. 2008;2:2121-34.
75. Song W, et al. Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles. Toxicol Lett. 2010;199:389-97.
76. Riedl MA, Nel AE. Importance of oxidative stress in the pathogenesis and treatment of asthma. Curr Opin Allergy Clin Immunol. 2008;8:49-56.
77. Pujalté I, et al. Cytotoxicity and oxidative stress induced by different metallic nanoparticles on human kidney cells. Part Fibre Toxicol. 2011;3:8-10.
78. Simkó M, Mattsson MO. Risks from accidental exposures to engineered nanoparticles and neurological health effects: A critical review. Part Fibre Toxicol. 2010;7:42.
79. Sarkar A, Das J, Manna P, Sil P. Nano-copper induces oxidative stress and apoptosis in kidney via both extrinsic and intrinsic pathways. Toxicology. 2011;290:209-18.
80. Barillet S, et al. Toxicological consequences of TiO2, SiC nanoparticles and multi-walled carbon nanotubes exposure in several mammalian cell types: an in vitro study. J Nanoparticle Res. 2010;12:61-73.
81. Heng B, et al. Evaluation of the cytotoxic and inflammatory potential of differentially shaped zinc oxide nanoparticles. Arch Toxicol. 2011;85:1517-28.
82. Yin R, et al. Acute lung inflammation in response to carbon nanoparticle exposure is augmented in the absence of NF-KB. Germany: ERS; 2010.
83. •• Zhou D, et al. Nanoparticle-induced unfolding of fibrogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol. 2010;6:39-44. This paper showed that the binding of certain nanoparticles to fibrinogen in plasma offers an alternative mechanism to the more commonly described role of oxidative stress in the inflammatory response to nanomaterials.
84. Pasparakis M. Regulation of tissue homeostasis by NF-kB signalling: implications for inflammatory diseases. Nat Rev Immunol. 2009;9:778-88.
85. Sitrin RG, Pan PM, Srikanth S, Todd 3rd RF. Fibrinogen activates NF-kB transcription factors in mononuclear phagocytes. J Immunol. 1998;161:1462-70. (Pubitemid 28380578)
86. Masamune A, et al. Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut. 2009;58:550-9.
87. Li Q, Verma IM. NF-kB regulation in the immune system. Nat Rev Immunol. 2009;2:725-34.
88. Pazin MJ, et al. NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev. 1996;10:37-49.
89. Silverman N, Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001;15:2321-42. (Pubitemid 32899738)
90. Ghosh S. May. M.J. Kopp EB. NF-kB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-60. (Pubitemid 28183365)
91. Hayden MS, Ghosh S. Shared principles in NF-kB signaling. Cell. 2008;132:344-62. (Pubitemid 351192002)
92. Hayden MS, Ghosh S. NF-kB in immunobiology. Cell Res. 2011;21:223-44.
93. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26:203-34.
94. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem. 2010;336:25-37.
95. Dobrovolskaia M, McNeil S. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2:469-78. (Pubitemid 47220069)
96. Tan Y, Li S, Pitt BR, Huang L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther. 1999;10:2153-61. (Pubitemid 29416295)
97. Mansur A, Karnik A, Frieri M. Nitric oxide production and apoptosis by gp 120. Allergy Asthma Proc. 2000;21:145-9.
98. Dzhindzhikhashvili M, Jaghab MA, Frieri M. Lymphadenopathy, productive cough, eosinophila and a new onset acquired immundeficiency syndrome. Allergy Asthma Proc. 2011;11:1-6.
99. Mansur A, Therattil J, Frieri M. An atypical case of hypogammaglobulinemia. Ann Allergy Asthma Immunol. 2000;84:583-6. (Pubitemid 30418857)
100. Frisella PD, Joks R, Frieri M. Transforming growth factor-beta. A Role in the upper airway and rhinosinusitis: D. Pteronyssinusi induced apoptosis with pulmonary alveolar cells. Am J Rhinol. 2011;25:231-5.
101. Frieri M. Accelerated atherosclerosis in systemic lupus erythematosus. Role of proinflammatory cytokines and therapeutic approaches. Curr Allergy Asthma Rep. 2011;12:25-32.
102. •• Frieri M, et al. Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J Nephrol. 2012. This is the first study that investigated the combined expression of TLR9 and VEGF, which could be an important tool for understanding the role of TLR9 and VEGF in lupus nephritis with insights into the early detection and targeted treatment.
103. Nishanth R, Jyotsna R. Schlager, J, Hussain, S., Reddanna, P. Inflammatory responses of RAW 264.7 macrophages upon exposure to nanoparticles: role of ROS-NFκB signaling pathway. Nanotoxicology. 2011;5:502-16.
104. Lishko VK, et al. Regulated unmasking of the cryptic binding site for integrin aMb2 in the gC-domain of fibrinogen. Biochemistry. 2002;41:12942-51. (Pubitemid 35215777)